APLM
Price
$6.71
Change
-$1.29 (-16.12%)
Updated
Apr 3, 04:59 PM (EDT)
Capitalization
7.4M
PHAR
Price
$7.65
Change
-$0.67 (-8.05%)
Updated
Apr 3, 04:59 PM (EDT)
Capitalization
547.81M
34 days until earnings call
Ad is loading...

APLM vs PHAR

Header iconAPLM vs PHAR Comparison
Open Charts APLM vs PHARBanner chart's image
Apollomics
Price$6.71
Change-$1.29 (-16.12%)
Volume$100
Capitalization7.4M
Pharming Group
Price$7.65
Change-$0.67 (-8.05%)
Volume$200
Capitalization547.81M
APLM vs PHAR Comparison Chart
Loading...
APLM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PHAR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
APLM vs. PHAR commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APLM is a Hold and PHAR is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (APLM: $8.00 vs. PHAR: $8.32)
Brand notoriety: APLM and PHAR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: APLM: 148% vs. PHAR: 205%
Market capitalization -- APLM: $7.4M vs. PHAR: $547.81M
APLM [@Biotechnology] is valued at $7.4M. PHAR’s [@Biotechnology] market capitalization is $547.81M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

APLM’s FA Score shows that 1 FA rating(s) are green whilePHAR’s FA Score has 1 green FA rating(s).

  • APLM’s FA Score: 1 green, 4 red.
  • PHAR’s FA Score: 1 green, 4 red.
According to our system of comparison, both APLM and PHAR are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

APLM’s TA Score shows that 7 TA indicator(s) are bullish while PHAR’s TA Score has 4 bullish TA indicator(s).

  • APLM’s TA Score: 7 bullish, 3 bearish.
  • PHAR’s TA Score: 4 bullish, 2 bearish.
According to our system of comparison, APLM is a better buy in the short-term than PHAR.

Price Growth

APLM (@Biotechnology) experienced а -1.96% price change this week, while PHAR (@Biotechnology) price change was -5.14% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.57%. For the same industry, the average monthly price growth was -10.69%, and the average quarterly price growth was -14.76%.

Reported Earning Dates

APLM is expected to report earnings on Mar 31, 2023.

PHAR is expected to report earnings on May 08, 2025.

Industries' Descriptions

@Biotechnology (-8.57% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PHAR($548M) has a higher market cap than APLM($7.4M). APLM YTD gains are higher at: -17.949 vs. PHAR (-23.994). PHAR has higher annual earnings (EBITDA): 7.56M vs. APLM (-56.38M). APLM has less debt than PHAR: APLM (4.72M) vs PHAR (127M). PHAR has higher revenues than APLM: PHAR (286M) vs APLM (0).
APLMPHARAPLM / PHAR
Capitalization7.4M548M1%
EBITDA-56.38M7.56M-746%
Gain YTD-17.949-23.99475%
P/E RatioN/AN/A-
Revenue0286M-
Total CashN/A172M-
Total Debt4.72M127M4%
TECHNICAL ANALYSIS
Technical Analysis
APLMPHAR
RSI
ODDS (%)
Bearish Trend 2 days ago
33%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
56%
Bearish Trend 16 days ago
89%
Momentum
ODDS (%)
Bullish Trend 2 days ago
54%
Bullish Trend 16 days ago
62%
MACD
ODDS (%)
Bearish Trend 2 days ago
42%
Bullish Trend 16 days ago
75%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 16 days ago
65%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
36%
Bearish Trend 16 days ago
82%
Advances
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 21 days ago
67%
Declines
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 23 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
61%
Bullish Trend 16 days ago
71%
Aroon
ODDS (%)
Bullish Trend 2 days ago
31%
N/A
View a ticker or compare two or three
Ad is loading...
APLM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PHAR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MRFIX57.60N/A
N/A
MFS Research I
GDEUX21.37N/A
N/A
Goldman Sachs U.S. Equity ESG R6
LADTX25.00N/A
N/A
Lord Abbett Developing Growth R5
PJVQX22.57N/A
N/A
PGIM Jennison Value R6
TRDIX8.00N/A
N/A
Transamerica Sustainable Equity Inc I2

APLM and

Correlation & Price change

A.I.dvisor indicates that over the last year, APLM has been loosely correlated with HCWB. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if APLM jumps, then HCWB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To APLM
1D Price
Change %
APLM100%
+14.29%
HCWB - APLM
48%
Loosely correlated
+0.28%
RVMD - APLM
33%
Loosely correlated
+2.91%
PHAR - APLM
31%
Poorly correlated
-3.46%
KURA - APLM
28%
Poorly correlated
+2.19%
ZIVO - APLM
28%
Poorly correlated
-7.89%
More

PHAR and

Correlation & Price change

A.I.dvisor tells us that PHAR and APLM have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PHAR and APLM's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PHAR
1D Price
Change %
PHAR100%
-8.11%
APLM - PHAR
31%
Poorly correlated
-16.13%
ADPT - PHAR
27%
Poorly correlated
-6.68%
IBRX - PHAR
27%
Poorly correlated
-2.62%
ATXS - PHAR
26%
Poorly correlated
-6.61%
SONN - PHAR
25%
Poorly correlated
-3.05%
More